Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the domestic business, sales growth in medical-use Kampo formulations, information-provision activities aligned with the needs of healthcare professionals, the consolidation of YOMEISHU SEIZO CO.,LTD. as a subsidiary, and an increase in the number of stores carrying general-use Kampo formulations and other products contributed to results. In the China business, the consolidation of 上海虹橋中薬飲片有限公司 contributed to higher revenue. Operating profit was affected by the consolidation of YOMEISHU SEIZO CO.,LTD. as a subsidiary, foreign exchange movements, and an increase in research and development expenses, among other factors. Ordinary income was affected by foreign exchange gains on loans to overseas subsidiaries, while net income was affected by the recognition of a gain on negative goodwill, among other factors.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥103,441 million (YoY +15.1%) |
| Operating profit | ¥18,848 million (YoY +10.1%) |
| Ordinary income | ¥20,316 million (YoY +23.7%) |
| Profit attributable to owners of the parent | ¥16,203 million (YoY +29.9%) |
| Net income per share | ¥217.36 |
| Equity ratio | End of the current fiscal period 51.7 / End of previous period 54.3 |
| Total assets | ¥657,399 million |
| Net assets | ¥395,788 million |
| Cash flows from operating activities | ¥17,620 million |
| Cash flows from investing activities | ¥-20,531 million |
| Cash flows from financing activities | ¥10,763 million |
| Cash and cash equivalents at end of period | ¥91,582 million |
| Full-year earnings forecast | Net Sales ¥218,500 million (YoY +13.4%) / Operating profit ¥38,400 million (YoY +9.0%) / Ordinary income ¥36,400 million (YoY -9.1%) / Profit attributable to owners of the parent ¥29,300 million (YoY +4.2%) / Net income per share ¥393.03 |
| Revision to Earnings Forecast | Net Sales ¥213,600 million → ¥218,500 million（+2.3%） / Operating profit ¥37,500 million → ¥38,400 million（+2.4%） / Ordinary income ¥35,500 million → ¥36,400 million（+2.5%） / Profit attributable to owners of the parent ¥26,200 million → ¥29,300 million（+11.8%） |
| Annual Dividend Forecast | ¥147 → ¥158（+7.5%） |
| Regional sales | Region Domestic / Net Sales ¥83,945 million / Year on year against the same period last year ¥5.5 million, Region China / Net Sales ¥19,495 million / Year on year against the same period last year ¥88.2 million |
| Depreciation and amortization | ¥6,926 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of property, plant and equipment / Amount ¥0 million, Item Gain on Sale of Investment Securities / Amount ¥1,368 million, Item Gain on negative goodwill / Amount ¥1,765 million / Extraordinary loss Item Loss on sale of non-current assets / Amount ¥0 million, Item Loss on Retirement of Fixed Assets / Amount ¥23 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate Yes / Restatement None |
| Changes in the scope of consolidation | New Number of companies 1 / Company name YOMEISHU SEIZO CO.,LTD. / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors, securities analysts and media organizations) |
| Issued Shares at Period-End | 76,758,362 Shares |
| Treasury Shares at Period-End | 2,206,328 Shares |
| Factors Behind Changes in Business Performance | In the domestic business, sales growth in medical-use Kampo formulations, information-provision activities aligned with the needs of healthcare professionals, the consolidation of YOMEISHU SEIZO CO.,LTD. as a subsidiary, and an increase in the number of stores carrying general-use Kampo formulations and other products contributed to results. In the China business, the consolidation of 上海虹橋中薬飲片有限公司 contributed to higher revenue. Operating profit was affected by the consolidation of YOMEISHU SEIZO CO.,LTD. as a subsidiary, foreign exchange movements, and an increase in research and development expenses, among other factors. Ordinary income was affected by foreign exchange gains on loans to overseas subsidiaries, while net income was affected by the recognition of a gain on negative goodwill, among other factors. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The consolidation of YOMEISHU SEIZO CO.,LTD. as a subsidiary, the consolidation of 上海虹橋中薬飲片有限公司, increased sales of medical-use Kampo formulations, information-provision activities for healthcare professionals, foreign exchange gains, and gains on the recognition of negative goodwill, among other factors.